164 related articles for article (PubMed ID: 33682120)
21. Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer ≥4 cm in size: an SEER-Medicare analysis.
Malhotra J; Mhango G; Gomez JE; Smith C; Galsky MD; Strauss GM; Wisnivesky JP
Ann Oncol; 2015 Apr; 26(4):768-773. PubMed ID: 25600562
[TBL] [Abstract][Full Text] [Related]
22. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
[TBL] [Abstract][Full Text] [Related]
23. Area-level variations in cancer care and outcomes.
Keating NL; Landrum MB; Lamont EB; Bozeman SR; McNeil BJ
Med Care; 2012 May; 50(5):366-73. PubMed ID: 22437623
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
[TBL] [Abstract][Full Text] [Related]
25. Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer.
Wang J; Kuo YF; Freeman J; Markowitz AB; Goodwin JS
Cancer; 2008 Jan; 112(2):382-90. PubMed ID: 18041068
[TBL] [Abstract][Full Text] [Related]
26. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Schvartsman G; Peng SA; Bis G; Lee JJ; Benveniste MFK; Zhang J; Roarty EB; Lacerda L; Swisher S; Heymach JV; Fossella FV; William WN
Lung Cancer; 2017 Oct; 112():90-95. PubMed ID: 29191606
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare.
Ramsey SD; Howlader N; Etzioni RD; Donato B
J Clin Oncol; 2004 Dec; 22(24):4971-8. PubMed ID: 15611512
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer.
Davidoff AJ; Tang M; Seal B; Edelman MJ
J Clin Oncol; 2010 May; 28(13):2191-7. PubMed ID: 20351329
[TBL] [Abstract][Full Text] [Related]
29. Survival of older patients with cancer in the Veterans Health Administration versus fee-for-service Medicare.
Landrum MB; Keating NL; Lamont EB; Bozeman SR; Krasnow SH; Shulman L; Brown JR; Earle CC; Rabin M; McNeil BJ
J Clin Oncol; 2012 Apr; 30(10):1072-9. PubMed ID: 22393093
[TBL] [Abstract][Full Text] [Related]
30. Trends in Low-Value Health Service Use and Spending in the US Medicare Fee-for-Service Program, 2014-2018.
Mafi JN; Reid RO; Baseman LH; Hickey S; Totten M; Agniel D; Fendrick AM; Sarkisian C; Damberg CL
JAMA Netw Open; 2021 Feb; 4(2):e2037328. PubMed ID: 33591365
[TBL] [Abstract][Full Text] [Related]
31. The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma.
Thornton Snider J; Batt K; Wu Y; Tebeka MG; Seabury S
Am J Manag Care; 2017 Oct; 23(10):e340-e346. PubMed ID: 29087638
[TBL] [Abstract][Full Text] [Related]
32. Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.
Langer C; Ravelo A; Hazard SJ; Guerin A; Ionescu-Ittu R; Latremouille-Viau D; Wu EQ; Ramalingam S
Lung Cancer; 2014 Dec; 86(3):350-7. PubMed ID: 25439437
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
[No Abstract] [Full Text] [Related]
34. Healthcare utilization and costs associated with COPD among SEER-Medicare beneficiaries with NSCLC.
Shah S; Blanchette CM; Coyle JC; Kowalkowski M; Arthur ST; Howden R
J Med Econ; 2018 Sep; 21(9):861-868. PubMed ID: 29857784
[TBL] [Abstract][Full Text] [Related]
35. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.
Garon EB; Hellmann MD; Rizvi NA; Carcereny E; Leighl NB; Ahn MJ; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Felip E; Goldman JW; Scalzo C; Jensen E; Kush DA; Hui R
J Clin Oncol; 2019 Oct; 37(28):2518-2527. PubMed ID: 31154919
[TBL] [Abstract][Full Text] [Related]
36. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.
Lee CK; Man J; Lord S; Cooper W; Links M; Gebski V; Herbst RS; Gralla RJ; Mok T; Yang JC
JAMA Oncol; 2018 Feb; 4(2):210-216. PubMed ID: 29270615
[TBL] [Abstract][Full Text] [Related]
37. Characteristics associated with the use of nonanatomic resections among Medicare patients undergoing resections of early-stage lung cancer.
Kim AW; Detterbeck FC; Boffa DJ; Decker RH; Soulos PR; Cramer LD; Gross CP
Ann Thorac Surg; 2012 Sep; 94(3):895-901. PubMed ID: 22835558
[TBL] [Abstract][Full Text] [Related]
38. Changes in health care spending and quality for Medicare beneficiaries associated with a commercial ACO contract.
McWilliams JM; Landon BE; Chernew ME
JAMA; 2013 Aug; 310(8):829-36. PubMed ID: 23982369
[TBL] [Abstract][Full Text] [Related]
39. Use and spending on antineoplastic therapy for Medicare beneficiaries with cancer.
Davidoff AJ; Shaffer T; Erten MZ; Shoemaker JS; Zuckerman IH; Pandya N; Stuart BC; Bryant-Comstock LG; Shenolikar R
Med Care; 2013 Apr; 51(4):351-60. PubMed ID: 23222498
[TBL] [Abstract][Full Text] [Related]
40. End-of-life care for lung cancer patients in the United States and Ontario.
Warren JL; Barbera L; Bremner KE; Yabroff KR; Hoch JS; Barrett MJ; Luo J; Krahn MD
J Natl Cancer Inst; 2011 Jun; 103(11):853-62. PubMed ID: 21593012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
